Maccura

What Maccura does

Maccura Biotechnology Co., Ltd. (迈克生物) is a Chinese in vitro diagnostics (IVD) company founded in 1994 and headquartered in Chengdu, listed on the Shenzhen Stock Exchange ChiNext board (ticker 300463). The company operates an integrated R&D, manufacturing, sales, and service model across eight IVD platforms: biochemistry, immunoassay, coagulation, blood cell analysis, urine analysis, molecular diagnostics, pathology, and blood transfusion. Core technology includes magnetic particle acridinium ester direct chemiluminescence, proprietary OsciDrop vibration-microdroplet digital PCR, and the LABAS family of laboratory automation pipelines (MAX, MIX, S-series, F9000X), supported by extensive analyte menus across 513 domestic registrations and 551 CE certifications.

Maccura serves hospital medical laboratories, clinical diagnostic centers, and medical research institutions in China and over 100 international markets, with a particular focus on three-tier and two-tier hospital laboratories plus county-level and primary care facilities undergoing intelligent laboratory transformation. The company developed first-in-China capabilities in metrological traceability, including CNAS medical reference laboratory accreditation (2013), JCTLM reference measurement service listing (2015), and IRMM partnership, enabling cross-institutional result comparability for DRG/DIP-era regional lab sharing. The go-to-market model combines direct enterprise field sales to large hospital customers with a nationwide dealer network, supported by a 24/7 service hotline and dedicated engineer infrastructure across all provinces.

The revenue model is anchored on hardware-plus-consumables placement: instruments are sold or placed at customer sites through enterprise contracts, generating recurring reagent and consumable revenue across the installed base. Additional revenue streams include laboratory design and consulting services, ISO 15189 accreditation support, and academic research collaborations. Customer reach spans approximately 7,000 end customers across all Chinese provinces, supplemented by international distribution through resellers. The company holds 671 patents as of May 2025 and operates from three Chengdu parks (Baichuan, Anhe, and Tianfu Bio-Town under construction).

Name

Maccura

Legal name

迈克生物股份有限公司

Website

https://maccura.com

Company type

Public

Founded year

1994

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Maccura Biotechnology is a Chinese in vitro diagnostics company (Shenzhen Stock Exchange: 300463) that develops, manufactures, and sells integrated IVD analyzers, reagents, and laboratory automation systems across eight platforms to hospitals, clinical laboratories, and research institutions in China and over 100 countries.

Ownership category

akta.pro rank

Product category

In Vitro Diagnostics (IVD)

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451), Medical and Diagnostic Laboratories (62151)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826), Services-Medical Laboratories (8071), Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047)

akta.pro primary industry

Laboratory Automation, Sample Prep & Liquid Handling (IVD Lab Diagnostics) (HLAHAAAN)

akta.pro secondary industries

IVD Reagents, Assay Kits & Consumables (Non-instrument) (HLAHAAAM), Clinical Chemistry & Immunoassay Systems (HLAHAAAA), Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays) (HLAAALAL), Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays) (HLAAALAO), Diagnostic & Triage Decision Support (HLACAGAA)

Keywords

• In vitro diagnostics
• Clinical chemistry analyzers
• Immunoassay systems
• Laboratory automation
• Diagnostic reagents

Headquarters

HQ city

Chengdu

HQ country

China

HQ region

Asia

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

1. IVD Instruments and Systems: Design, manufacturing and sale of automated in vitro diagnostic instruments including chemistry analyzers, immunoassay systems, hematology analyzers, coagulation analyzers, urine analyzers, molecular diagnostic systems, and laboratory automation lines. Instruments are sold with配套试剂 and maintained through service contracts.
2. IVD Reagents and Consumables: Comprehensive reagent portfolio covering tumor markers, infectious diseases, thyroid function, cardiac markers, reproductive hormones, and more across biochemistry, immunology, molecular and other platforms. Reagents are sold as配套产品 alongside instruments, with配套校准品和质控品.
3. Laboratory Services and Solutions: 提供医学实验室整体解决方案，包括实验室设计规划、认可评审辅导、现场精益管理、学术科研合作等服务，通过增值服务提升客户黏性。

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels5 records

Core offering

Maccura designs, manufactures, and sells in vitro diagnostic (IVD) instruments, reagents, and laboratory automation systems covering eight diagnostic platforms: biochemistry, immunoassay, coagulation, blood transfusion, blood cell analysis, urine analysis, molecular diagnostics, and pathology. The company offers automated analyzers, a comprehensive reagent menu, and integrated smart laboratory solutions sold primarily to hospitals and medical laboratories.

Product overview

Maccura is an in vitro diagnostics company offering a comprehensive portfolio of diagnostic products across eight platforms: biochemistry, immunoassay, coagulation, blood cell analysis, urine analysis, molecular diagnostics, pathology, and blood transfusion. The product architecture follows a platform-based model with automated assembly lines (LABAS MAX, LABAS MIX, LABAS S series, LABAS F9000) as the core automation infrastructure, supported by specialized analyzers (i3000/i1000/i800/i6000 chemiluminescence systems, C2000/C1000/C800 biochemical analyzers, H5000/H2600 coagulation systems, urine analyzers, digital PCR systems, blood cell analyzers) and extensive reagent menus. The MALAB intelligent software system connects all analyzers with LIS systems, while the 「智汇」 smart laboratory solution provides the overarching integration framework for complete laboratory automation and intelligent management.

Differentiator

Problem solved

Functional benefit

Brands

• 智汇实验室 (maiCARE): Intelligent/smart laboratory solution brand integrating automated lab systems, AI-powered software, and professional services to create a 'testing data factory + intelligent decision center' for medical laboratories.
• 迈 (MAGAZINE)
• 迈克学院
• 迈克杯

Products and services

• LABAS MAX Automated Sample Processing System Full laboratory intelligent automation assembly line that integrates blood analysis, immunoassay, biochemical, and coagulation detection platforms with intelligent software for complete sample processing workflow automation. Designed for hospital medical laboratories requiring high-throughput flexible integration.
• LABAS MIX Full Laboratory Intelligent Assembly Line Innovative integrated sample processing system with automatic QC detection, multi-mode sampling, automatic centrifugation, sample quality monitoring, one-click extraction, and ten integrated functions for medical laboratories.
• LABAS F9000X Automated Blood Analysis Workstation Complete blood testing solution integrating blood routine analysis, specific protein analysis, glycated hemoglobin analysis, and automatic slide making/staining with intelligent workflow management. Single-tube blood testing solution reduces blood collection volume and improves patient experience.
• LABAS S Series Automated Biochemistry-Immunoassay Assembly Line Integrated biochemistry-immunology assembly line featuring i6000 chemiluminescence system and C1000/C2000 biochemical analyzers with minimal footprint sample processing capabilities.
• i3000 Automated Chemiluminescence Immunoassay Analyzer High-speed chemiluminescence immunoassay system with magnetic particle acridinium ester direct chemiluminescence technology, processing 300 tests/hour with flexible module combinations.

Quantifiable outcome

• 670+ end customers covered across all provinces in China
• +3 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature6 records

Partnerships

Six partnerships are on record, tiered minor and core.

• 江苏省免疫学会minorStrategic or Co-development Partner · 1 February 2025迈克生物与江苏省免疫学会共同设立联合基金，用于支持免疫学相关的临床研究、学术交流和技术创新。合作旨在促进产学医研协同创新，推动免疫诊断技术的发展应用。
• 国际临床化学与检验医学联合会 (IFCC)coreStrategic or Co-development Partner2010年成为IFCC企业会员，参与国际检验医学标准化工作，与全球IVD行业领导者共同推动检验医学量值溯源和标准化发展。
• 欧盟标准物质委员会 (IRMM)coreStrategic or Co-development Partner成为IRMM合作成员，承担国际参考物质的赋值工作，参与国际标准物质定值，彰显在量值溯源领域的国际领先地位。
• 中国合格评定国家认可委员会 (CNAS)coreStrategic or Co-development Partner参考系统部通过CNAS医学参考实验室认可(2013年)，持续扩项至38项，是国内获得最多认可项目的企业参考实验室。
• 国际检验医学溯源联合委员会 (JCTLM)coreStrategic or Co-development Partner2015年参考系统部进入JCTLM医学参考测量实验室列表，为国际检验医学溯源联合委员会认可的参考测量服务提供商。
• 高校合作院校minorStrategic or Co-development Partner与重庆医药高等专科学校、四川卫生康复职业学院、四川大学华西医学院、电子科技大学等高校建立迈克学院合作项目，进行校企合作人才培养。

Scale indicators8 records

Recent moves8 records

Expansion highlights5 records

Broad incumbents

• Siemens Healthineers: Global IVD incumbent (Atellica, ADVIA Centaur) with strong presence in lab automation. Directly comparable to Maccura's LABAS automation strategy and competes for the same tier-3 hospital and reference-lab accounts internationally.
• Mindray: Largest Chinese medical device company with a substantial IVD division spanning chemistry, immunoassay, hematology, and lab automation. Competes with Maccura across nearly all of its 8 IVD platforms but operates at meaningfully larger scale with a broader global footprint.
• Roche Diagnostics: Global IVD leader offering cobas chemistry/immunoassay systems, lab automation, and reference standards. Comparable as a benchmark for premium-tier positioning, international distribution scale, and the standards-based moat (JCTLM/IRMM) that Maccura is replicating in China.
• Beckman Coulter Diagnostics: Global IVD player in chemistry, immunoassay, hematology, and lab automation (DxA/DxH/AU/DxI platforms). Comparable to Maccura across multiple platforms and serves as a key competitor for premium lab automation contracts in emerging markets.
• Abbott Diagnostics: Global IVD incumbent (ARCHITECT, Alinity series) competing against Maccura in chemistry, immunoassay, and lab automation globally. Relevant comparator for international expansion ambitions and high-volume hospital lab contracts.

Direct peers

• Dirui Industrial: Chinese IVD company with overlapping exposure to urinalysis, clinical chemistry, and lab automation. Directly comparable to Maccura in the urine analysis segment and competes for similar hospital laboratory customers in China.
• Snibe (Shenzhen New Industries Biomedical Engineering): Shenzhen-listed Chinese IVD company that, like Maccura, specializes in chemiluminescence immunoassay analyzers and reagent menus for hospital laboratories. Closely comparable product portfolio, customer base (tier 2/3 Chinese hospitals), and business model (instruments plus reagent pull-through).
• Autobio Diagnostics: Major Chinese IVD peer competing across immunoassay, microbiology, and clinical chemistry. Overlaps with Maccura on the same reagent + instrument + automation model serving Chinese hospital and clinical laboratory customers.

Emerging players

• KingMed Diagnostics: Largest independent clinical laboratory network in China, offering IVD testing services using Maccura and competitor platforms. Comparable as a downstream customer/ecosystem participant whose purchasing decisions influence Maccura's reagent volumes in China.
• Da An Gene (DaAn Gene / Kinghawk): Chinese molecular diagnostics player with overlapping nucleic-acid-testing capabilities relevant to Maccura's digital PCR (OsciDrop) push. Comparable on the molecular diagnostics platform and as a competitor for hospital molecular testing tenders.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments3 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Maccura